CA-RECOVER
Three leading companies in the textiles industry, Recover™, Happy Punt, and Hansae, have entered into a multi-year partnership agreement to provide end-to-end solutions for the design, development, and production of sustainably conscious apparel for the fashion industry. The partnership allows retailers and brands to seamlessly integrate sustainable Recover™ recycled cotton fiber into their products, thereby helping to solve one of the world’s biggest environmental issues.
Using innovative technology, the partnership provides a range of services, including 3D design, patterns, tech packs, samples, and production to support brands and retailers at every step in the supply chain. The partnership offers a unique speed to market solution for the production of fully sustainable apparel and leverages the group’s global reach, with offices in Seoul, Barcelona, and New York. In addition, close customer proximity provides in-market technical design services that develop, review and approve all specifications to ensure correct fit and brand enhancing products.The partnership also provides an end-to-end service that combines the advantages of production nearshore and offshore worldwide.
Dedicated leading edge design and development facilities can produce samples in house from concept to finished sample with a quick turnaround time. Notably, as part of a joint sustainability initiative, the partnership also encourages R&D designs to be replaced by 3D designs to reduce the environmental impact of the sampling process.
The three leading companies have a combined experience of over 130 years in each of their respective fields. Each firm’s commitment to bringing the best technology to the product and the market offers a disruptive approach to the traditional apparel design and production process. The partnership is proud to be actively working with leading global brands to deliver sustainable collections to the market by Spring 2022, and more collections are expected to follow.
Recover™ will increase its production to 200,000 metric tons of recycled cotton fiber per year by 2025 to support the current market demand. This recycled cotton volume will save nearly three trillion liters of water each year, equivalent to the drinking water consumed by 3 billion people on an annual basis and allow 500,000 acres of land to be directed away from cotton cultivation to other uses.
The Recover™, Happy Punt, and Hansae strategic partnership provides brands and retailers with an easy plug & play solution to achieve their sustainability initiatives and ensures a quality product for the consumer.
About Recover™
Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.
As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
For more information, visit www.recovertex.com and follow @recoverfiber on social media.
About Happy Punt
Happy Punt is a design and manufacturing end-to-end solution provider to the fashion industry, applying virtual design tools supported by the best technology offering an efficient and sustainable product development and design process. Founded in 1996, Happy Punt has more than 25 years of history in the fashion business, and a team of 80 fashion designers and PD&D. Happy Punt offers a “Gold Standard” of excellence in technical and production know-how that ensures the manufacturing and delivery of safe and reliable products by providing a global end-to-end service recognized for the quality of their fashion design and for the speed of their creative process.
About Hansae
Established in 1982, Hansae Co., Ltd. has maintained consistent growth through specialized apparel exports and annually produces over 300 million garments. Hansae has 14 global corporations in 7 countries, over 600 people at the corporate Headquarters, and over 35,000 in the global manufacturing workforce.
Its mission is to enrich customer’s lives and lead fashion culture by providing the best quality clothes at a reasonable price. Quality management systems maximize values for its customers by ensuring manufacturing excellence and on-time, safe delivery of products.
Hansae has developed HAMS, its own smart factory system to maximize the efficiency of production plants in Vietnam, Indonesia, Myanmar, Nicaragua, Guatemala, and Haiti.
Hansae aims to be a front-runner in sustainable management by establishing ‘10% For Good’, pledging to donate 10 percent of its net profits from sustainable orders to third parties that work toward improving ocean environment by collecting wastes, the advancement of green raw materials, and hardware upgrades and retrofits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005776/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom